Pitolisant Gets Orphan Drug Status for Idiopathic Hypersomnia
The Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisant for the treatment of idiopathic hypersomnia.
Stay updated with breaking news from Kumar Budur. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisant for the treatment of idiopathic hypersomnia.
Harmony announced new data from its phase 2 study evaluating pitolisant for excessive daytime sleepiness in Prader-Willi syndrome.
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and...
The FDA has granted Orphan Drug designation to pitolisant for the treatment of idiopathic hypersomnia.
The FDA has granted Harmony Biosciences Orphan Drug Designation for pitolisant for the treatment of idiopathic hypersomnia.